지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.7
- 수록면
- 455 - 463 (9page)
이용수
초록· 키워드
오류제보하기
Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable progress in IBD therapy. Some patients, however, do not respond to anti-TNF treatment, or their response decreases over time. This phenomenon highlights the need to identify new molecular targets for therapy in IBD. The targets of new therapeutic molecules in IBD must aim to restore immune dysregulation by the inhibition of proinflammatory cytokines (TNF-α, interleukin [IL]-6, IL-13, IL-17, IL-18, and IL-21) and augmentation of the effect of anti-inflammatory cytokines (IL-10, IL-11, and transforming growth factor β) and to pursue new anti-inflammatory targets, such as regulatory T-cell therapy, Smad7 antisense, Janus-activated kinase inhibition, Toll-like receptor stimulation, leukocyte adhesion, and blockade of T-cell homing via integrins and mucosal addressin cellular adhesion molecule-1. In addition, potential molecular targets could restore mucosal barrier function and stimulate mucosal healing. Despite these potential targets, the value and clinical significance of most new molecules remain unclear, and clinical efficacy and safety must be better defined before their implementation in clinical practice. This article aims to review the promising and emerging molecular targets that could be clinically meaningful for novel therapeutic approaches.
목차
등록된 정보가 없습니다.
참고문헌 (59)
참고문헌 신청
Holtmann MH / 2006 / From immunogenic mechanisms to novel therapeutic approaches in inflammatory bowel disease / Adv Exp Med Biol 579:227~242
Molodecky NA / 2012 / Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review / Gastroenterology 142:46~54.e42
Gabbani T / 2016 / The genetic burden of inflammatory bowel diseases: implications for the clinic / Expert Rev Gastroenterol Hepatol 10:1109~1117
Vogelaar L / 2009 / The impact of biologics on health-related quality of life in patients with inflammatory bowel disease / Clin Exp Gastroenterol 2:101~109
Bernstein CN / 2012 / Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). Hospitalisations and surgery in Crohn’s disease / Gut 61:622~629
Molodecky NA / 2012 / Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review / Gastroenterology 142:46~54.e42
Gabbani T / 2016 / The genetic burden of inflammatory bowel diseases: implications for the clinic / Expert Rev Gastroenterol Hepatol 10:1109~1117
Vogelaar L / 2009 / The impact of biologics on health-related quality of life in patients with inflammatory bowel disease / Clin Exp Gastroenterol 2:101~109
Bernstein CN / 2012 / Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). Hospitalisations and surgery in Crohn’s disease / Gut 61:622~629
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
Gut and Liver
2020 .01
-
Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies
Immune Network
2017 .02
-
Mechanism-based Drug Therapy of Inflammatory Bowel Disease With Special Reference to Rheumatic Disease
대한류마티스학회지
2020 .01
-
Mucosal Immunity Related to FOXP3+ Regulatory T Cells, Th17 Cells and Cytokines in Pediatric Inflammatory Bowel Disease
Journal of Korean Medical Science
2018 .01
-
Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
Intestinal research
2023 .04
-
Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease
Gut and Liver
2019 .01
-
Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients
Journal of Korean Medical Science
2017 .01
-
Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know?
Intestinal research
2021 .01
-
Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease
Intestinal research
2020 .01
-
Targeted Immunotherapy for Autoimmune Disease
Immune Network
2022 .02
-
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Intestinal research
2023 .01
-
Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
Intestinal research
2017 .01
-
Immunological pathogenesis of inflammatory bowel disease
Intestinal research
2018 .01
-
Inflammatory bowel disease pathogenesis mediated by Th17 cells: cytokines, microbiota, and therapies
Journal of Biomedical and Translational Research
2024 .06
-
Indigo Naturalis in Inflammatory Bowel Disease: mechanisms of action and insights from clinical trials
Journal of Pharmacopuncture
2024 .06
-
Landscape of inflammatory bowel disease in Singapore
Intestinal research
2022 .07
-
우리나라 염증장질환의 현황
대한의사협회지
2021 .09
-
Novel inflammatory bowel disease (IBD) specific electronic medical record allows scalable auditing of IBD severity, therapy and complications to show the current unmet need in IBD care
Intestinal research
2022 .10
-
Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
Gut and Liver
2017 .01
-
Navigating the Microbial Basis of Inflammatory Bowel Diseases: Seeing the Light at the End of the Tunnel
Gut and Liver
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0